TherapeuticsMD (NASDAQ:TXMD) Announces Quarterly Earnings Results

TherapeuticsMD (NASDAQ:TXMD) posted its quarterly earnings data on Monday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($6.12) by $6.07, reports. TherapeuticsMD had a net margin of 10.80% and a return on equity of 0.27%. The company had revenue of $0.89 million for the quarter, compared to analyst estimates of $19.77 million.

TherapeuticsMD Stock Performance

Shares of TherapeuticsMD stock opened at $2.02 on Wednesday. The firm has a market cap of $23.37 million, a PE ratio of -202.00 and a beta of 0.51. The firm’s 50-day simple moving average is $2.29 and its 200-day simple moving average is $1.77. TherapeuticsMD has a 1 year low of $0.84 and a 1 year high of $2.95.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TherapeuticsMD stock. Citadel Advisors LLC grew its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 125.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 34,273 shares of the company’s stock after acquiring an additional 19,073 shares during the quarter. Citadel Advisors LLC owned about 0.30% of TherapeuticsMD worth $36,000 as of its most recent filing with the SEC. 30.74% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of TherapeuticsMD from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, January 12th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.